PharmEnable Therapeutics Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
PharmEnable Therapeutics is a biotechnology research company that applies artificial intelligence to discover small-molecule medicines for disease targets inaccessible to antibodies. It aims to deliver molecules with antibody-like specificity and selectivity and is building a wholly owned pipeline focused on oncology and neurology, while also pursuing collaborative drug-discovery programs for difficult targets. The company is based in Histon and Impington, England, near Cambridge, and it is a spinoff of the University of Cambridge. Within the biotech landscape, it positions itself at the intersection of AI-assisted discovery and small-molecule therapeutics. A notable recent development is a collaboration announced in October 2023 with Sosei Heptares Group to combine their capabilities for a neurological disease target.